TrialPanorama/TrialPanorama-database huggingface dataset:
Study: NCT02360735

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Manual Lymphatic Drainage
Description: Manual Lymphatic Drainage (MLD) is a specialized massage technique utilized to decrease various forms of edema. This technique promotes reuptake of interstitial fluid along the pathways of the lymphatic system. This technique promotes healing, decrease swelling, and decrease pain.

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Physical Therapy
Description: All patients will participate in joint physical therapy classes during their inpatient stay.

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Physical Therapy
Description: All patients will participate in joint physical therapy classes during their inpatient stay.
Study: NCT03406078

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Tezepelumab
Description: Tezepelumab subcutaneous injection

Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Placebo subcutaneous injection
Study: NCT02874313

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Pharmacological treatment
Description: Conventional pharmacological treatment with oral antidiabetic drugs or insulin

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Conventional anti-diabetic diet recommendations

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Conventional anti-diabetic diet recommendations
Study: NCT01673178

Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: 0.9% w/v sodium chloride injection, United States Pharmacopeia (USP), once a week for 4 weeks

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: 25 mg PF-05231023
Description: 25 mg IV once a week for 4 weeks
Study: NCT00831662

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Diquafosol tetrasodium ophthalmic solution, 2%
Description: One to two drops in each eye QID for 6 weeks

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: One to two drops in each eye QID for 6 weeks
Study: NCT02720120

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Ocrelizumab
Description: Participants will receive single IV infusion of ocrelizumab at 400, 1000, 1500, and 2000 mg.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Ocrelizumab
Description: Participants will receive single IV infusion of ocrelizumab at 400, 1000, 1500, and 2000 mg.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Ocrelizumab
Description: Participants will receive single IV infusion of ocrelizumab at 400, 1000, 1500, and 2000 mg.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Ocrelizumab
Description: Participants will receive single IV infusion of ocrelizumab at 400, 1000, 1500, and 2000 mg.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Ocrelizumab
Description: Participants will receive single IV infusion of ocrelizumab at 400, 1000, 1500, and 2000 mg.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Ocrelizumab
Description: Participants will receive single IV infusion of ocrelizumab at 400, 1000, 1500, and 2000 mg.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Ocrelizumab
Description: Participants will receive single IV infusion of ocrelizumab at 400, 1000, 1500, and 2000 mg.

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Participants will receive single IV infusion of placebo.
Study: NCT01413503

Intervention type: RADIATION
Group type: EXPERIMENTAL
Intervention: 131I-MIBG
Description: Therapeutic 131I-MIBG will be synthesized at Nuclear Diagnostic Products (NDP; Rockaway, New Jersey) with specific activities of 9-18 Ci/mmole. The therapeutic dose: 8-12 mCi/kg (maximum 1200 mCi ± 10% at investigator's discretion) will be diluted in 25 ml of normal saline, and will be infused intravenously through a patient's peripheral or central line over 120 minutes. The patient will remain in a radiation protected isolation room until radiation emissions are ≤ 2 mr/hr at a 1 meter distance or meets institutional and state guidelines. This usually takes 4-6 days. In all cases, special shielding will be equipped in the room to minimize exposure to the outside environment and personnel will observe institutional radiation safety precautions.
Study: NCT01675453

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: 7.2% NaCl plus 6% hydroxyethyl starch 200/0.5

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: 0.9% NaCl
Study: NCT03686423

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Exercise Program
Description: The exercise program will combine moderate intensity aerobic exercise with lower-extremity specific resistance training. A moderate level of intensity will be calculated based on results from a maximal graded exercise test (VO2R) conducted prior to the intervention.
Study: NCT01673178

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: 50 mg PF-05231023
Description: 50 mg IV once a week for 4 weeks

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: 100 mg PF-05231023
Description: 100 mg IV once a week for 4 weeks

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: 150 mg PF-05231023
Description: 150 mg IV once a week for 4 weeks
Study: NCT04474886

Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Fresubin® powder fibre
Description: 2 servings per day
Study: NCT02246153

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Laparoscopic gastrectomy
Description: * After exclusion of T4b, bulky lymph nodes, or distant metastasis case by diagnostic laparoscopy, laparoscopic distal subtotal gastrectomy and D2 lymph node dissection will be performed with curative treated intent.~* The type of reconstruction will be selected according to the surgeon's experience and anastomotic procedure is performed extracorporeally using a mini-laparotomy.

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Open gastrectomy
Description: * After exclusion of T4b, bulky lymph nodes, or distant metastasis case by diagnostic laparoscopy, open distal subtotal gastrectomy and D2 lymph node dissection will be performed with curative treated intent.~* The type of reconstruction will be selected according to the surgeon's experience.
Study: NCT04137289

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: BI 905711
Description: BI 905711

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: BI 905711
Description: BI 905711

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: BI 905711
Description: BI 905711

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: BI 905711
Description: BI 905711
Study: NCT03724357

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Vaxchora
Description: One dose. Approximately 100 mL of cold or room temperature purified bottled water is placed into a clean disposable cup. The contents of the buffer sachet are added to the water and stirred. Then the contents of the active (lyophilized vaccine) sachet are added to the water and stirred for approximately 30 seconds. The reconstituted mixture should be completely ingested within 15 minutes.
Study: NCT00254553

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Testim 1% (testosterone gel)
Description: Testim_ 100 mg: two tubes of 50 mg of Testim_per day

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: two tubes of placebo per day
Study: NCT00280592

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Cranberry
Description: Dry essence of cranberry presented as 18 mg of proanthocyanidines sachets of powdered cranberry. Cranberry juice is administered twice a day (in the morning and in the evening).

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Placebo presented as sachets of powder. Placebo juice is administered twice a day (in the morning and in the evening).
Study: NCT02712957

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: NEO6860
Description: TRPV1 antagonist

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: NEO6860 placebo
Description: Inactive substance

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: NEO6860 placebo
Description: Inactive substance

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Naproxen
Description: NSAID

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Naproxen placebo
Description: inactive substance

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Naproxen placebo
Description: inactive substance
Study: NCT03174015

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Bauleni Secret
Description: The intervention will invite enrolled landlords to a series of meetings in which various mechanisms will be used, each designed to increase their likelihood of improving the toilet(s) on their plot. These meetings will be the main vehicle for a status-building campaign associated with increasing wealth by improving plot sanitation, understanding tenants' implicit demand, understanding the processes by which toilets can be improved, and a competition rewarding landlords that make the greatest improvements to the improvement of their toilet(s).
Study: NCT01104883

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Adductor-Canal-Blockade
Description: US-guided Adductor-Canal-Blockade with ropivacaine 7,5 mg/ml

Intervention type: PROCEDURE
Group type: PLACEBO_COMPARATOR
Intervention: Adductor-Canal-blockade with saline
Description: US-guided Adductor-Canal-blockade with saline
Study: NCT01664676

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Liraglutide

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo-liraglutide
Study: NCT05155748

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Continuous education and knowledge exchange
Description: The intervention is educational and directed at the complete nursing home care team.
Study: NCT01754064

Intervention type: DEVICE
Intervention: Cardiac Rhythm Management device
Study: NCT02573259

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: PF-06801591
Description: IV every 21 days (Part 1)

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: PF-06801591
Description: IV every 21 days (Part 1)

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: PF-06801591
Description: IV every 21 days (Part 1)

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: PF-06801591
Description: IV every 21 days (Part 1)

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: PF-06801591
Description: 300 mg SC every 28 days (Part 1 and 2)
Study: NCT00631254

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Allergen challenge
Description: Conventional allergen challenge: increasing allergen doses given by nebulisation through the mouth and stopped when a 20% fall in forced expiratory volume in one second is obtained.~Low dose allergen challenge: very low allergen doses given by nebulisation through the mouth. No more than a 5% fall in forced expiratory volume in one second.~Nasal allergen challenge: One drop of increasing allergen doses on nasal mucosa.

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Allergen challenge
Description: Low dose allergen challenge: very low allergen doses given by nebulisation through the mouth. No more than a 5% fall in forced expiratory volume in one second.~Nasal allergen challenge: One drop of increasing allergen doses on nasal mucosa.
Study: NCT03158168

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Candida Antigen
Description: Candida Albicans Antigen injection

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Zinc Sulfate
Description: Zinc Sulfate injection
Study: NCT00190424

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: CpG-ODN
Study: NCT04036721

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Prolonged glucocorticosteroid (prednisone) regimen
Description: Prolongation of maintenance therapy with prednisone of patients with pneumonitis inducted by anyi-PD-1/anti-PD-L1 antibodies.

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Short glucocorticosteroid (prednisone) regimen
Description: Prednison regimen based upon American Society of Clinical Oncology and European Society for Medical Oncology Clinical Practice Guidelines on pneumonitis treatment in patients receiving immunotherapy agents
Study: NCT01138020

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Cognitive Intervention
Description: Cognitive rehabilitation treatment designed specifically to address the most common cognitive complaints in executive and memory function

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Educational intervention
Description: Educational intervention is geared at personal management of TBI-related symptoms.
Study: NCT03188055

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Best Case/Worst Case communication tool
Description: The communication tool promotes dialogue and patient deliberation, and supports shared decision making in the context of life-limiting illness. Building on a conceptual model of shared decision-making proposed and the practice of scenario planning our intervention is designed to lead to a discussion of patient preferences and consideration of outcomes.~The surgeon verbally describes the best case, worst case, and most likely outcomes for each treatment option-incorporating rich narrative from clinical experience and translation of probabilistic information-while drawing a diagram of those options. The surgeon also writes details about each option on the diagram. The narrative and graphic help family and patients formulate and express preferences.
Study: NCT03163407

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Norepinephrine
Description: Treatment of the postspinal anesthesia hypotension by administrating 5 mcg of Norepinephrine intravenously every 3 min until normal systolic blood pressure

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Ephedrine
Description: Management of the post spinal hypotension by administrating 6 mg of Ephedrine intravenously every 3 min
Study: NCT02154438

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Ketamine
Description: ketamine 0.5mg/kg loading followed by 0.5mg/kg/h infusion during operation
Study: NCT02316639

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Neuromuscular Training
Description: The established Neuromuscular Training (NMT) protocol is supervised, progressive program in which the patient maintains balance on three different support surfaces while a clinician administers purposeful manipulations of the support system.1 The patient maintains a single-leg stance on the rollerboard and tiltboard surfaces, and a two-leg stance with one foot on a roller board while the other is on a platform. Participants will complete two training sessions per week, for five weeks for a total of 10 training sessions.

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Neuromuscular Training
Description: The established Neuromuscular Training (NMT) protocol is supervised, progressive program in which the patient maintains balance on three different support surfaces while a clinician administers purposeful manipulations of the support system.1 The patient maintains a single-leg stance on the rollerboard and tiltboard surfaces, and a two-leg stance with one foot on a roller board while the other is on a platform. Participants will complete two training sessions per week, for five weeks for a total of 10 training sessions.
Study: NCT03030625

Intervention type: RADIATION
Group type: OTHER
Intervention: IGRT/VMAT focal therapy boost to DIL
Description: Image-guided/VMAT focal Intensification dose to intraprostatic dominant lesion in men with localized prostate cancer (PCa) of intermediate and high risk (criteria NCCN) eligible to receive radiotherapy
Study: NCT00763789

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: local anaesthesia and remifentanil sedation

Intervention type: OTHER
Group type: OTHER
Intervention: total intravenous anaesthesia
Study: NCT01859182

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: selumetinib
Description: Given PO

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Akt inhibitor MK2206
Description: Given PO

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: laboratory biomarker analysis
Description: Correlative studies

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: pharmacogenomic studies
Description: Correlative studies

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: quality-of-life assessment
Description: Ancillary studies
Study: NCT00974363

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Blood Sampling
Description: A blood sample will be taken yearly at each long-term follow-up visit (i.e. Year 2 through Year 5) after vaccination during the primary study. No vaccines are administered in the long-term follow-up study
Study: NCT04137289

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: BI 905711
Description: BI 905711
Study: NCT03312413

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Dexmedetomidine Hydrochloride
Description: Dexmedetomidine Hydrochloride 0.2 μg·kg-1·h-will be administered to participants by intravenous infusion from incision to 20-30 minutes before the end of surgery

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Normal Saline
Description: Normal saline 0.5 mL·h-1 will be administered to participants by intravenous infusion from incision to 20-30 minutes before the end of surgery

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Dexmedetomidine Hydrochloride
Description: Dexmedetomidine Hydrochloride 0.5 μg·kg-1·h-1 will be administered to participants by intravenous infusion from incision to 20-30 minutes before the end of surgery

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Dexmedetomidine Hydrochloride
Description: Dexmedetomidine Hydrochloride 0.7 μg·kg-1·h-1 will be administered to participants by intravenous infusion from incision to 20-30 minutes before the end of surgery
Study: NCT03064399

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: without lateral ligament repairment
Description: microfracture without repairment of the lateral ligament

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: lateral ligament repairment
Description: microfracture combined with repairment of the lateral ligament
Study: NCT02539459

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Everolimus
Description: 10 mg tablets
Study: NCT00447564

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Probuphine
Description: 4 implants

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: placebo
Description: 4 implants
Study: NCT04295967

Intervention type: OTHER
Intervention: formalin fixed paraffin embedded blocks
Description: The study will be conducted using formalin fixed paraffin embedded blocks of seventy cases of urothelial carcinomas .CD31-PAS dual-staining will be performed to confirm the presence of VM.

Intervention type: OTHER
Intervention: formalin fixed paraffin embedded blocks
Description: The study will be conducted using formalin fixed paraffin embedded blocks of seventy cases of urothelial carcinomas .CD31-PAS dual-staining will be performed to confirm the presence of VM.
Study: NCT01640639

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Thalidomide
Description: Thalidomide, pill, 50 mg, once p.d., 6 weeks

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Placebo, pill, once p.d., 6 weeks
Study: NCT03957369

Intervention type: DIAGNOSTIC_TEST
Intervention: HIV-1 plasma RNA Genotyping secuencing by Sanger technique
Description: After signing informed consent, we will collect whole blood for HIV genotyping in plasma HIV-1 RNA for testing of resistance-associated mutations to reverse transcriptase, protease, and integrase enzymes.

Intervention type: DIAGNOSTIC_TEST
Intervention: HIV-1 plasma RNA Genotyping secuencing by Ultra-deep sequencing technique
Description: After signing informed consent, we will collect whole blood for HIV genotyping in plasma HIV-1 RNA for testing of resistance-associated mutations to reverse transcriptase, protease, and integrase enzymes.
Study: NCT01406470

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Immune Globulin Intravenous (Human) 5% Liquid, IVIG-SN™
Description: IVIG-SN™ 10g/200mL, dose is 300-900 mg/kg/infusion every 21 or 28 days, intravenously. The total duration of treatment with IVIG-SN™ will be 12 months with a 3 month follow-up.
Study: NCT01721928

Intervention type: DEVICE
Intervention: Continuous venovenous hemodialysis
Description: Continuous venovenous hemodialysis
Study: NCT00680992

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Denosumab
Description: 120 mg administered subcutaneously (SC) every 4 weeks (Q4W) with a loading dose of 120 mg SC on study days 8 and 15.
Study: NCT00974363

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Blood Sampling
Description: A blood sample will be taken yearly at each long-term follow-up visit (i.e. Year 2 through Year 5) after vaccination during the primary study. No vaccines are administered in the long-term follow-up study
Study: NCT00808067

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: dabigatran dose 1
Description: dabigatran high dose twice daily

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: dabigatran dose 2
Description: dabigatran low dose twice daily
Study: NCT04321421

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: hyperimmune plasma
Description: administration of hyperimmune plasma at day 1 and based on clinical response on day 3 and 5
Study: NCT02275429

Intervention type: PROCEDURE
Group type: OTHER
Intervention: Blood test
Description: blood will be drawn the day before the race (day 0), upon completion of the race (between 27 and 67 hours after departure), and on days 7 and 28
Study: NCT00513305

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Arsenic trioxide
Description: Arsenic trioxide will be administered intravenously (iv) at a dose of 0.25 mg/kg.

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Low-dose cytarabine alone
Description: Cytarabine will be administered at a dose of 10 mg/m\^2 subcutaneously (sc) twice a day (bid).

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Low-dose cytarabine alone
Description: Cytarabine will be administered at a dose of 10 mg/m\^2 subcutaneously (sc) twice a day (bid).
Study: NCT02922504

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Music intervention group

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Controlled group
Study: NCT03049553

Intervention type: DEVICE
Group type: OTHER
Intervention: Cobas HPV-DNA test
Description: Cobas HPV-DNA testing device from Roche is already in standard use in the Danish screening program for purpose of triage and primary screening of women 60+. It has four signals; HPV-negative, HPV-16, HPV-18 and other